415 Summer St, Boston, MA 02210
ABOUT CHINA FOCUS @BWB
China has embraced a vigorously growing healthcare market in the past decade. Ever since joining ICH in 2017, China has seen increased clinical trials and accelerated new drug and device approval. For biotech and MedTech companies outside of China, you need to find the right partners and the right resources to bring your products to China, in order to adapt to the difference in culture, regulation, reimbursement, etc. In the meantime, Chinese biotechs are actively seeking global market entry opportunities and oversea partners.
China Focus @BWB is designed to provide a meaningful platform to inform, inspire, and foster cross-border partnership in life science and healthcare.
- Investors (VC, PE, investment bank, etc.)
- Life science innovators and entrepreneurs
- Biotech & big pharma
- Medtech (device and diagnostics) manufacturers and distributors
- Service providers (law firm, financial advisory, regulatory consulting, CRO, CDMO, etc.)
- Healthcare providers
- Regulatory reforms in China and the impact on cross-border partnership
- Chines biopharma’s strategies to meet the domestic and global needs for innovation
- Join forces in a global battle again cancer
- Cell and gene therapy – opportunities for collaboration
- Winning recipes in a competitive landscape of licensing
- Learn about Chinese life science and healthcare industry
- Hear about the latest Chinese regulatory reforms and implications
- Meet with the decision makers in the industry
- Initiate business conversations that otherwise difficult to start

Attendees
%
Executive Level Attendees
Chinese Companies and Investors
One-to-one meetings
TO
EXPECT
complimentary registration
Download Sample Attendee List from past China Focus events
Download Program from past China Focus events
Room | Theme | Time |
254A | MyBioGate Global Healthcare Innovation Competition | 9 AM – 12:30 PM |
Pitch & Match | 1:00 PM – 3 PM | |
254B | Exhibition and Partnering | 10 AM – 3:30 PM |
255 | Plenary session (including Simcere Salon) | 8:30 AM – 5:20 PM |
254 A&B | Reception (sponsored by Simcere Innovation, Inc.) | 5:20 PM - 7:00 PM |
Time | Plenary session (Room 255) |
8:30 AM - 9:10 AM | Opening Remark Katherine Anderson - Head of U.S. Life Science & Healthcare Relationship Banking, Silicon Valley Bank |
9:10 AM - 10:10 AM | Panel 1: Cross-border partnership in a new era of globalization and innovation Moderator: Mark Young - Co-founder & Managing Partner, Bridge Point Capital Panelists: Lei (Geffrey) Gao - Executive VP/Deputy General Manager, Harbin Pharma Qingxi (Charles) Wang - Executive President of International Division and Executive Director of the Board, CSPC Pharmaceutical Group Travis McCready - President & CEO, Massachusetts Life Sciences Center Konstantin Poukalov - Perceptive Advisors |
10:10 AM - 10:30 AM | Break |
10:30 AM - 11:00 AM | Featured Talk: Regulatory reforms in China and the impact on cross-border partnership in the healthcare industry Haishan Xiong - Senior VP Business Development, FMD K&L |
11:00 AM - 12:00 PM | Panel 2: Chinese biopharma’s diverse strategies to meet the domestic and global needs of innovation Moderator: Danhui Wang - Founding Partner, Remedeca Partners LLC Panelists: Xiyong (Sean) Fu - President, Luye Boston R&D LLC Lijun Wu - Chief Scientific Officer, Fosun Pharma US Miguel Forte - CEO, Zelluna Immunotherapy; CCO, the International Society for Cell and Gene Therapy |
12:00 PM - 1:00 PM | Lunch break |
1:00 PM - 1:20 PM | Featured Talk: Current status and outlook of CAR-T therapy in China Wei (William) Cao - CEO, Gracell Biotechnologies |
1:20 PM - 2:10 PM | Panel 3: China’s growing role in a global battle against cancer Moderator: Laura Benjamin - President & CEO, Oncologie Panelists: Xiangyang (Sean) Zhang - CEO, Hengrui Therapeutics Wei (William) Cao - CEO, Gracell Biotechnologies Hua Mu - Chief Medical Officer, Simcere Pharmaceutical Group |
2:10 PM - 2:50 PM | Chinese company showcase |
2:50 PM - 3:10 PM | Break |
3:10 PM - 4:00 PM | Panel 4 (partnering with TORREYA): Winning recipes in a competitive landscape of licensing - What can we learn from the experiences of recent deal makers? Moderator: Jie Liu - Managing Director, Torreya Partners Panelists: Jiawen Han - Head of Business Development (USA), Qilu Pharmaceutical Samuel Murphy - VP and Head of International Business Development, Salubris Pharmaceuticals Anna Vardanyan - Executive Director of Business Development and Alliance Management, Everest Medicines Jack Wu - Head of Business Development (USA), Adlai Nortye Biopharma |
4:00 PM - 7:00 PM | SIMCERE SALON (complimentary registration needed) Special Talk: Understanding and curing rare diseases worldwide Harvey Lodish - Founding Partner and Professor, Whitehead Institute of Biomedical Research/MIT Special Talk: PD-1 cancer immunotherapy Gordon Freeman - Professor of Medical Oncology, Dana-Farbar Cancer Institute/ Harvard Medical School Special Talk: The drug regulatory reform and accelerating new drug development in China Alex Xu - Chief Scientist, CDE/NMPA "Simcere Innovation in Boston" Shawn Xu - Executive Director, Simcere Innovation, Inc. Networking (Room 254A&B - drinks and refreshment provided) |
Katherine Andersen
Head of U.S. Life Science & Healthcare Relationship Banking
Silicon Valley Bank
Laura Benjamin
President and CEO
Oncologie
Wei (William) Cao
Chairman and CEO
Gracell Biotechnologies
Miguel Forte
CEO - Zelluna Immunotherapy
CCO - the International Society for Cell and Gene Therapy
Gordon Freeman
Professor of Medical Oncology
Dana-Farber Cancer Center/Harvard Medical School
Xi-Yong (Sean) Fu
President
Luye Boston R&D LLC
Lei (Geffrey) Gao
Executive VP/Deputy General Manager
Harbin Pharma
Jiawen Han
Head of Business Development (USA)
Qilu Pharmaceutical
Jie (Jay) Liu
Managing Director
Torreya Partners
Harvey Lodish
Founding Member and Professor
Whitehead Institute of Biomedical Research/MIT
Travis McCready
President and CEO
Massachusetts Life Sciences Center
Hua Mu
Chief Medical Officer
Simcere Pharmaceutical Group
Samuel Murphy
VP and Head of International BD
Salubris Pharmaceuticals
Konstantin Poukalov
Perceptive Advisors
Anna Vardanyan
Executive Director, Business Development and Alliance Management
Everest Medicines
Danhui Wang
Founding partner
Remedeca Partners LLC
Qingxi (Charles) Wang
Executive President of International Division and Business Development, Executive Director of the Board
CSPC Pharmaceutical Group Ltd.
Jack Wu
Head of Business Development (USA)
Adlai Nortye Biopharma

Lijun Wu
CSO
Fosun Pharma US
Haishan Xiong
Senior VP Business Development
FMD K&L
Xiangbin (Shawn) Xu
Executive Director
Simcere Innovation, Inc.
Zengjun (Alex) Xu
Chief Scientist
CDE/NMPA
Mark Young
Co-founder & Managing Partner
Bridge Point Capital
Xiangyang (Sean) Zhang
CEO
Hengrui Therapeutics
EVENT PARTNERS







